San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy ...

Illumina raises Q4 and FY24 revenue outlook, expects solid margins, with projected 2024 EPS between $4.12 and $4.14.

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep, powered by SOMAmer technology, a next-generation sequencing (NGS) based solution that will help scale access ...

Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 ...

The Truveta team at its Bellevue, Wash., headquarters last year. (Truveta Photo) Seattle-area health data company Truveta ...

The global Spatial Genomics & Transcriptomics market is expected to grow to USD 995.7 Million by 2029, up from USD 554.5 ...

Nvidia Corp. announced tie-ups with Illumina Inc., the Mayo Clinic and other health-care organizations as part of its push to ...

Illumina (ILMN) announced it is collaborating with Nvidia (NVDA) to advance technology platforms for the analysis and interpretation of ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation ...